Introduction Atrial fibrillation (AF)-induced cardiomyopathy (AIC) is retrospectively defined after normalisation of left ...

According to this new report, the global cardiac biomarkers testing market is estimated to be valued at US$ 5.7 billion in the year 2028, growing at a CAGR of 8.5% in the period 2020 to 2028. Growth ...

ROACH: My husband is 73 and was diagnosed with heart failure and a severely dilated left ventricle. At the time, he was pumping 10 liters per minute. He had a proBNP natriuretic peptide level over ...

Peptides are amino acid polymers. They are generally much smaller than proteins and don’t have sufficient activity on their own – they generally represent a small portion of a full protein ...

Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...

The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...

A collection of studies presented at a recent American Heart Association (AHA) conference has confirmed the heart health benefits provided by the new anti-obesity drugs, semaglutide and tirzepatide, ...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against the other ...

Biomarin has a near $3bn per annum drug franchise, and is profitable. Elliott Investment Management may be attempting to ...

The following is a summary of “Parenteral prostacyclin utilization in patients with pulmonary arterial hypertension in the intermediate-risk strata: a retrospective chart review and cross-sectional ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the flagship journal of the American College of Cardiology, ...

In positive early data from the RCT, sacubitril/valsartan given over 24 weeks reduced signs of heart damage in cancer ...